HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Conditions
Advanced Breast Cancer
What is the purpose of this trial?
The purpose of this study is to determine the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), of oral vorinostat in combination with oral capecitabine given on days 1-7 and 15-21 of a 28 day cycle in patients with advanced breast cancer, using RECIST criteria.
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Female
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Merck
Yale University - Dates:
- December 2008
- Last Updated:
- Oct 08, 2009
- Study HIC#:
- 0803003591
Clinicaltrials.gov ID: NCT00719875
For more information about this trial, contact:
Noelle Sowers
203-737-3472
noelle.sowers@yale.edu
Investigator
Maysa Abu-Khalaf, MBBS
Principal Investigator
